Agalactosylated IgG antibodies depend on cellular Fc receptors for in vivo activity
Open accessThe DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Abstract
IgG antibodies are glycoproteins containing a branched sugar moiety attached to the asparagine 297 residue in the antibody constant region (Fc). This glycan is essential for maintaining a functional Fc structure, which is a prerequisite for antibody-mediated effector functions, such as the interaction with cellular Fc receptors or the complement component C1q. Variations in the composition of the sugar moiety can dramatically influence antibody activity. Moreover, humans and mice with autoimmune disorders, such as rheumatoid arthritis, have altered IgG glycosylation patterns with increased levels of antibodies lacking terminal sialic acid and galactose residues (IgG-G0). There is great interest in understanding whether this altered glycosylation pattern influences antibody-mediated effector functions.In vitro studies have suggested that IgG-G0 antibodies gain the capacity to activate the complement pathway via mannose-binding lectin (MBL), which could contribute to antibody-mediated inflammation. We have analyzed the activity of IgG-G0 antibodies in mice with a genetic deletion of MBL (MBL-null mice) and demonstrate that IgG-G0 antibodies are unimpaired in MBL-null mice. In contrast, the activity of these antibody glycovariants is fully dependent on the presence of activating Fc receptors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Shields, R. L., Lai, J., Keck, R., O'Connell, L. Y., Hong, K., Meng, Y. G., Weikert, S. H. A., & Presta, L. G. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m202069200 · Cited by 1,835
Anti-Inflammatory Activity of Immunoglobulin G Resulting from Fc Sialylation
Kaneko, Y., Nimmerjahn, F., & Ravetch, J. V. (2006) · Science · doi:10.1126/science.1129594 · Cited by 1,754
Self-citationDeisenhofer, J. (1981) · PubMed · Cited by 1,422
Shinkawa, T., Nakamura, K., Yamane, N., Shoji-Hosaka, E., Kanda, Y., Sakurada, M., Uchida, K., Anazawa, H., Satoh, M., Yamasaki, M., et al. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m210665200 · Cited by 1,413
Deisenhofer, J. (1981) · Biochemistry · doi:10.1021/bi00512a001 · Cited by 1,333
The Impact of Glycosylation on the Biological Function and Structure of Human Immunoglobulins
Arnold, J. N., Wormald, M. R., Sim, R. B., Rudd, P. M., & Dwek, R. A. (2007) · Annual Review of Immunology · doi:10.1146/annurev.immunol.25.022106.141702 · Cited by 1,307
Fcγ Receptors: Old Friends and New Family Members
Nimmerjahn, F., & Ravetch, J. V. (2006) · Immunity · doi:10.1016/j.immuni.2005.11.010 · Cited by 1,072
Self-citationDivergent Immunoglobulin G Subclass Activity Through Selective Fc Receptor Binding
Nimmerjahn, F., & Ravetch, J. V. (2005) · Science · doi:10.1126/science.1118948 · Cited by 1,037
Self-citationMalhotra, R., Wormald, M. R., Rudd, P. M., Fischer, P. B., Dwek, R. A., & Sim, R. B. (1995) · Nature Medicine · doi:10.1038/nm0395-237 · Cited by 786
Arthritis Critically Dependent on Innate Immune System Players
Ji, H., Ohmura, K., Mahmood, U., Lee, D. M., Hofhuis, F. M. A., Boackle, S. A., Takahashi, K., Holers, V. M., Walport, M., Gerard, C., et al. (2002) · Immunity · doi:10.1016/s1074-7613(02)00275-3 · Cited by 693
Cited by
Fcγ receptors as regulators of immune responses
Nimmerjahn, F., & Ravetch, J. V. (2008) · Nature Reviews Immunology · doi:10.1038/nri2206 · Cited by 2,947
“More recent data, however, argues against the involvement of the lectin pathway of complement activatio”
BackgroundSelf-citationVarki, A. (2017) · Glycobiology · doi:10.1093/glycob/cww086 · Cited by 2,635
Intravenous immunoglobulin therapy: how does IgG modulate the immune system?
Schwab, I., & Nimmerjahn, F. (2013) · Nature Reviews Immunology · doi:10.1038/nri3401 · Cited by 820
Self-citationFerrara, C., Grau, S., Jäger, C., Sondermann, P., Brünker, P., Waldhauer, I., Hennig, M., Ruf, A., Rufer, A. C., Stihle, M., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1108455108 · Cited by 770
“For example, murine agalactosylated IgG has a slightly higher affinity toward the activating FcγRIII, whereas the affinity to the inhibiting FcγRIIb receptor is reduced, which may explain the enhanced proportion of this glycoform in an autoimmune setting (6).”
BackgroundSis, B., Mengel, M., Haas, M., Colvin, R. B., Halloran, P. F., Racusen, L. C., Solez, K., Baldwin, W. M., Bracamonte, E. R., Broecker, V., et al. (2010) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2009.02987.x · Cited by 762
Sialic acids as regulators of molecular and cellular interactions
Schauer, R. (2009) · Current Opinion in Structural Biology · doi:10.1016/j.sbi.2009.06.003 · Cited by 673
Anti-Inflammatory Actions of Intravenous Immunoglobulin
Nimmerjahn, F., & Ravetch, J. V. (2008) · Annual Review of Immunology · doi:10.1146/annurev.immunol.26.021607.090232 · Cited by 525
Self-citationOmics-Driven Systems Interrogation of Metabolic Dysregulation in COVID-19 Pathogenesis
Song, J.-W., Lam, S. M., Fan, X., Cao, W.-J., Wang, S.-Y., Tian, H., Chua, G. H., Zhang, C., Meng, F.-P., Xu, Z., et al. (2020) · Cell Metabolism · doi:10.1016/j.cmet.2020.06.016 · Cited by 520
A robust, high-throughput assay to determine the phagocytic activity of clinical antibody samples
Ackerman, M. E., Moldt, B., Wyatt, R. T., Dugast, A.-S., McAndrew, E., Tsoukas, S., Jost, S., Berger, C. T., Sciaranghella, G., Liu, Q., et al. (2011) · Journal of Immunological Methods · doi:10.1016/j.jim.2010.12.016 · Cited by 450
Fc‐Receptors as Regulators of Immunity
Nimmerjahn, F., & Ravetch, J. V. (2007) · Advances in Immunology · doi:10.1016/s0065-2776(07)96005-8 · Cited by 418
Self-citationImmunoglobulin G glycosylation in aging and diseases
Gudelj, I., Lauc, G., & Pezer, M. (2018) · Cellular Immunology · doi:10.1016/j.cellimm.2018.07.009 · Cited by 408
Fc glycans of therapeutic antibodies as critical quality attributes
Reusch, D., & Tejada, M. L. (2015) · Glycobiology · doi:10.1093/glycob/cwv065 · Cited by 404
An overview of autoantibodies in rheumatoid arthritis
van Delft, M. A. M., & Huizinga, T. W. J. (2020) · Journal of Autoimmunity · doi:10.1016/j.jaut.2019.102392 · Cited by 398
Evaluation of the serum N ‐linked glycome for the diagnosis of cancer and chronic inflammation
Arnold, J. N., Saldova, R., Hamid, U. M. A., & Rudd, P. M. (2008) · PROTEOMICS · doi:10.1002/pmic.200800163 · Cited by 307
Advances in the assessment and control of the effector functions of therapeutic antibodies
Jiang, X.-R., Song, A., Bergelson, S., Arroll, T., Parekh, B., May, K., Chung, S., Strouse, R., Mire-Sluis, A., & Schenerman, M. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3365 · Cited by 299
Antibody‐mediated modulation of immune responses
Nimmerjahn, F., & Ravetch, J. V. (2010) · Immunological Reviews · doi:10.1111/j.1600-065x.2010.00910.x · Cited by 285
Self-citationvan de Geijn, F. E., Wuhrer, M., Selman, M. H., Willemsen, S. P., de Man, Y. A., Deelder, A. M., Hazes, J. M., & Dolhain, R. J. (2009) · Arthritis Research & Therapy · doi:10.1186/ar2892 · Cited by 274
Sialylation of IgG Fc domain impairs complement-dependent cytotoxicity
Quast, I., Keller, C. W., Maurer, M. A., Giddens, J. P., Tackenberg, B., Wang, L.-X., Münz, C., Nimmerjahn, F., Dalakas, M. C., & Lünemann, J. D. (2015) · Journal of Clinical Investigation · doi:10.1172/jci82695 · Cited by 269
Self-citationAntibody fucosylation differentially impacts cytotoxicity mediated by NK and PMN effector cells
Peipp, M., Lammerts van Bueren, J. J., Schneider-Merck, T., Bleeker, W. W. K., Dechant, M., Beyer, T., Repp, R., van Berkel, P. H. C., Vink, T., van de Winkel, J. G. J., et al. (2008) · Blood · doi:10.1182/blood-2008-03-144600 · Cited by 222
Peschke, B., Keller, C. W., Weber, P., Quast, I., & Lünemann, J. D. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00646 · Cited by 219
“For murine IgG2b and IgG1, it has been demonstrated that addition of terminal galactose increases binding of C1q (28).”
BackgroundWada, R., Matsui, M., & Kawasaki, N. (2019) · mAbs · doi:10.1080/19420862.2018.1551044 · Cited by 186
Glycoproteomic Analysis of Antibodies
Zauner, G., Selman, M. H. J., Bondt, A., Rombouts, Y., Blank, D., Deelder, A. M., & Wuhrer, M. (2013) · Molecular & Cellular Proteomics · doi:10.1074/mcp.r112.026005 · Cited by 172
Inflammaging and human longevity in the omics era
Monti, D., Ostan, R., Borelli, V., Castellani, G., & Franceschi, C. (2017) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2016.12.008 · Cited by 167
The role and function of Fcγ receptors on myeloid cells
Bournazos, S., Wang, T. T., & Ravetch, J. V. (2016) · Microbiology Spectrum · doi:10.1128/microbiolspec.mchd-0045-2016 · Cited by 138
“Indeed, genetic deletion of the Asn297 site or enzymatic removal of the Fc-associated glycan abrogates the capacity of the Fc domain to interact with Fc γ Rs (14 – 17).”
BackgroundSelf-citationProduction of α2,6-sialylated IgG1 in CHO cells
Raymond, C., Robotham, A., Spearman, M., Butler, M., Kelly, J., & Durocher, Y. (2015) · mAbs · doi:10.1080/19420862.2015.1029215 · Cited by 106
Glycosylation shapes the efficacy and safety of diverse protein, gene and cell therapies
Rocamora, F., Peralta, A. G., Shin, S., Sorrentino, J., Wu, M. Y. M., Toth, E. A., Fuerst, T. R., & Lewis, N. E. (2023) · Biotechnology Advances · doi:10.1016/j.biotechadv.2023.108206 · Cited by 67
Blondeel, E. J. M., & Aucoin, M. G. (2018) · Biotechnology Advances · doi:10.1016/j.biotechadv.2018.06.008 · Cited by 46
Kim, S.-M., Chang, K.-H., & Oh, D. J. (2018) · Biotechnology and Bioprocess Engineering · doi:10.1007/s12257-018-0109-8 · Cited by 11
Gomathinayagam, S., Laface, D., Houston-Cummings, N. R., Mangadu, R., Moore, R., Shandil, I., Sharkey, N., Li, H., Stadheim, T. A., & Zha, D. (2015) · Journal of Biotechnology · doi:10.1016/j.jbiotec.2015.05.005 · Cited by 9
Metadata
- Authors
- Nimmerjahn, F., Anthony, R. M., & Ravetch, J. V.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 2007-05-15
- Volume
- 104
- Issue
- 20
- Pages
- 8433-8437
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W1977510035
- Cited by
- 253
- References
- 38
- FWCI
- 9.58
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.